Search Results

Twelve-Month CARENET Data Presented for InspireMD's CGuard Carotid EPS

November 20, 2015—InspireMD, Inc. announced positive 12-month follow-up data from the CARENET trial, which evaluated the company’s CGuard carotid embolic protective stent system (EPS) featuring MicroNet technology.

Preliminary 2-Year PARADIGM 101 Results Presented for InspireMD's CGuard EPS

December 5, 2017—InspireMD announced the preliminary 24-month follow-up results from the PARADIGM 101 clinical study utilizing the company's CGuard embolic protection system (EPS).

Expanded 2-Year Results Reported From the PARADIGM Clinical Study of InspireMD's CGuard EPS

May 30, 2018—InspireMD announced that expanded 24-month follow-up results from the PARADIGM-Extend clinical study using the company's CGuard embolic protection system (EPS) were presented by Professor Piotr Musiałek, MD, at EuroPCR 2018, held May 21–25 in Paris, France.

Long-Term Data Presented From European Registries of InspireMD's CGuard EPS

November 29, 2018—InspireMD, Inc. announced that updated data on the company's CGuard embolic prevention system (EPS) for the prevention of stroke caused by the treatment of carotid artery disease were presented at the 45th annual VEITHsymposium held November 13–17 in New York, New York.

Full Market Launch of InspireMD's CGuard Announced at CIRSE

September 28, 2015—InspireMD, Inc. announced the full market launch of the CGuard embolic prevention system for the treatment of carotid artery disease, which is available through its strategic distribution partner, Penumbra, Inc. The announcement was made at CIRSE 2015, the Cardiovascular and Interventional Radiological Society of Europe annual scientific meeting being held September 26–30 in Lisbon, Portugal.

InspireMD’s CGuard Embolic Prevention System Data Presented at LINC

June 9, 2022—InspireMD, Inc. announced highlights from presentations and a live case featuring the company’s CGuard embolic prevention stent (EPS) system at LINC 2022, the Leipzig Interventional Course held June 6-9 in Leipzig, Germany.

InspireMD CGuard EPS Evaluated in Published 12-Month PARADIGM Results

June 10, 2020—InspireMD, Inc. announced that 12-month results from PARADIGM study of the company’s CGuard embolic prevention system for the prevention of stroke caused by carotid artery disease were published online by Adam Mazurek, MD, et al in EuroIntervention.

InspireMD's CGuard RX Approved in Europe, 6-Month CARENET Data Presented

January 27, 2015—InspireMD, Inc. announced that it received European CE Mark approval for the CGuard RX rapid exchange system for the company’s MicroNet covered carotid stent technology. The company also announced that positive 6-month follow-up data from its CGuard CARENET (Carotid Embolic Protection Study Using MicroNet) trial were presented at LINC 2015: The Leipzig Interventional Course in Leipzig, Germany.

Thirty-Day Data Presented From PARADIGM-EXTEND Study of InspireMD’s CGuard EPS Device

September 3, 2020—InspireMD, Inc. announced the presentation of updated data from the large, long-term PARADIGM-EXTEND study of the company’s CGuard embolic prevention system (EPS), as part of the European Society of Cardiology (ESC) 2020 Carotid Update e-presentation at ESC Congress 2020—The Digital Experience, held online as a virtual event August 29 to September 1, 2020.

Preliminary 3-Year Data From PARADIGM-Extend Trial Evaluate InspireMD's CGuard EPS

September 27, 2018—InspireMD, Inc. announced that findings from the PARADIGM-Extend trial of the company's CGuard MicroNet-covered embolic prevention system (EPS) were presented in a poster at TCT 2018, the Transcatheter Cardiovascular Therapeutics annual scientific symposium held September 21–25 in San Diego, California.

Magneto Thrombectomy Solutions’ eTrieve Catheter for PE Evaluated in FIH Study in Europe

May 10, 2022—Magneto Thrombectomy Solutions, an Israel-based medical device company developing thrombectomy solutions for the treatment of ischemic stroke and pulmonary embolism (PE), announced that first-in-human (FIH) results demonstrated safety and feasibility of the company’s eTrieve system in patients with acute PE.

CARENET 30-Day Data Presented for InspireMD's CGuard EPS

September 16, 2014—InspireMD, Inc. announced positive results from the CARENET trial for its CGuard embolic protection system (EPS).

CARENET 30-Day Data Published for InspireMD's CGuard Carotid EPS

August 17, 2015—Prof.

InspireMD Announces Study on Clinical Benefit and Utility of the CGuard EPS

October 19, 2016—InspireMD, Inc. announced the publication of positive 6-month clinical results on the company’s carotid CGuard double-layered embolic prevention stent (EPS) in patients with symptomatic or high-grade asymptomatic internal carotid artery (ICA) stenosis.